ZA943465B - Transforming growth factor alpha H1 - Google Patents

Transforming growth factor alpha H1

Info

Publication number: ZA943465B
Authority: ZA; South Africa
Prior art keywords: alpha; polypeptide; growth factor; transforming growth; factor alpha
Prior art date: 1994-03-08

Application number

ZA943465A

Other languages

English (en)

Inventor

Paul S Meissner

Rebeca Fuldner

Mark D Adams

Original Assignee

Human Genome Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-03-08

Filing date

1994-05-19

Publication date

1995-11-20

1994-05-19 Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc

1995-11-20 Publication of ZA943465B publication Critical patent/ZA943465B/xx

Links

NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 title 1
102000006747 Transforming Growth Factor alpha Human genes 0.000 title 1
101800004564 Transforming growth factor alpha Proteins 0.000 title 1
229920001184 polypeptide Polymers 0.000 abstract 5
108090000765 processed proteins & peptides Proteins 0.000 abstract 5
102000004196 processed proteins & peptides Human genes 0.000 abstract 5
239000005557 antagonist Substances 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
230000001225 therapeutic effect Effects 0.000 abstract 2
101500027527 Homo sapiens Transforming growth factor alpha Proteins 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
239000008024 pharmaceutical diluent Substances 0.000 abstract 1
230000000069 prophylactic effect Effects 0.000 abstract 1
238000010188 recombinant method Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Zoology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Toxicology (AREA)
Immunology (AREA)
Wood Science & Technology (AREA)
Endocrinology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Urology & Nephrology (AREA)
Crystallography & Structural Chemistry (AREA)
Ophthalmology & Optometry (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

ZA943465A 1994-03-08 1994-05-19 Transforming growth factor alpha H1 ZA943465B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/208,008 US5633147A (en)	1994-03-08	1994-03-08	Transforming growth factor αH1

Publications (1)

Publication Number	Publication Date
ZA943465B true ZA943465B (en)	1995-11-20

Family

ID=22772852

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA943465A ZA943465B (en)	1994-03-08	1994-05-19	Transforming growth factor alpha H1

Country Status (14)

Country	Link
US (1)	US5633147A (zh)
EP (2)	EP1063293A3 (zh)
JP (1)	JPH09509846A (zh)
KR (1)	KR970701776A (zh)
CN (1)	CN1087344C (zh)
AT (1)	ATE205254T1 (zh)
AU (1)	AU681406B2 (zh)
CA (1)	CA2184583A1 (zh)
DE (1)	DE69428214T2 (zh)
DK (1)	DK0759067T3 (zh)
ES (1)	ES2161246T3 (zh)
PT (1)	PT759067E (zh)
WO (1)	WO1995024466A1 (zh)
ZA (1)	ZA943465B (zh)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6608182B1 (en) *	1994-03-08	2003-08-19	Human Genome Sciences, Inc.	Human vascular endothelial growth factor 2
US7109308B1 (en)	1994-03-08	2006-09-19	Human Genome Sciences, Inc.	Antibodies to human vascular endothelial growth factor 2
US20020188110A1 (en) *	1994-03-08	2002-12-12	Human Genome Sciences, Inc.	Transforming growth factor alpha HI
US6074839A (en) *	1994-03-08	2000-06-13	Human Genome Sciences, Inc.	Transforming growth factor αHI
US7153827B1 (en) *	1994-03-08	2006-12-26	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2 and methods of use
US7186688B1 (en)	1994-03-08	2007-03-06	Human Genome Sciences, Inc.	Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
ATE309360T1 (de) *	1994-03-08	2005-11-15	Human Genome Sciences Inc	Vaskularer endothelialer wachstumsfaktor 2
US6734285B2 (en)	1994-03-08	2004-05-11	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2 proteins and compositions
US6040157A (en) *	1994-03-08	2000-03-21	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2
US5932540A (en)	1994-03-08	1999-08-03	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2
US6030613A (en)	1995-01-17	2000-02-29	The Brigham And Women's Hospital, Inc.	Receptor specific transepithelial transport of therapeutics
US6410506B1 (en)	1995-05-19	2002-06-25	Human Genome Sciences, Inc.	Transforming growth factor α HII
US8212004B2 (en)	1999-03-02	2012-07-03	Human Genome Sciences, Inc.	Neutrokine-alpha fusion proteins
US6812327B1 (en)	1996-10-25	2004-11-02	Human Genome Sciences, Inc.	Neutrokine-alpha polypeptides
US7294482B2 (en) *	1998-11-19	2007-11-13	Millennium Pharmaceuticals, Inc.	EGF-like nucleic acids
WO2000029438A1 (en) *	1998-11-19	2000-05-25	Millennium Pharmaceuticals, Inc.	Egf-like nucleic acids and polypeptides and uses thereof
US7223724B1 (en) *	1999-02-08	2007-05-29	Human Genome Sciences, Inc.	Use of vascular endothelial growth factor to treat photoreceptor cells
US20020099008A1 (en) *	1999-04-26	2002-07-25	Daniel R. Twardzik	Method for stimulating hematopoiesis using tgf-alpha
ATE364315T1 (de) *	1999-04-26	2007-07-15	Applied Protein Sciences Llc	Tgf-alpha polypeptide, funktionelle fragmente und verfahren zu ihrer anwendung
US20020193301A1 (en)	1999-08-19	2002-12-19	Stem Cell Pharmaceuticals, Inc.	TGF-alpha polypeptides, functional fragments and methods of use therefor
WO2001012127A2 (en) *	1999-08-19	2001-02-22	Stem Cell Pharmaceuticals, Inc.	TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR
US7879328B2 (en)	2000-06-16	2011-02-01	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to B lymphocyte stimulator
CA2407910C (en)	2000-06-16	2013-03-12	Steven M. Ruben	Antibodies that immunospecifically bind to blys
NZ518077A (en) *	2000-08-04	2003-11-28	Human Genome Sciences Inc	Biologically active fragments, analogues and derivatives of VEGF-2 for the treatment of peripheral artery diseases such as critical limb ischemia and coronary disease
US20030091565A1 (en)	2000-08-18	2003-05-15	Beltzer James P.	Binding polypeptides and methods based thereon
GB0020953D0 (en) *	2000-08-24	2000-10-11	Smithkline Beecham Biolog	Vaccine
US20030170786A1 (en) *	2001-04-13	2003-09-11	Rosen Craig A.	Vascular endothelial growth factor 2
WO2002083704A1 (en) *	2001-04-13	2002-10-24	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2
US7402312B2 (en) *	2001-04-13	2008-07-22	Human Genome Sciences, Inc.	Antibodies to vascular endothelial growth factor 2 (VEGF-2)
WO2002083849A2 (en) *	2001-04-13	2002-10-24	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2
US20050232921A1 (en) *	2001-04-13	2005-10-20	Rosen Craig A	Vascular endothelial growth factor 2
WO2004089357A2 (en) *	2003-04-02	2004-10-21	Regents Of The University Of Minnesota	Anti-fungal formulation of triterpene and essential oil
US9168286B2 (en)	2005-10-13	2015-10-27	Human Genome Sciences, Inc.	Methods and compositions for use in treatment of patients with autoantibody positive disease
US8211649B2 (en)	2006-03-31	2012-07-03	Human Genome Sciences, Inc.	Methods of diagnosing and prognosing hodgkin's lymphoma
KR101622412B1 (ko) *	2007-10-19	2016-05-18	제넨테크, 인크.	시스테인 조작된 항-ｔｅｎｂ２ 항체 및 항체 약물 접합체

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI890312A (fi) *	1988-01-25	1989-07-26	Oncogen	Amfiregulin: ett nytt bifunktionellt tillvaext modulerande glykoprotein.
US5115096A (en) *	1988-04-15	1992-05-19	Oncogen	Amphiregulin: a bifunctional growth modulating glycoprotein
US5256643A (en) *	1990-05-29	1993-10-26	The Government Of The United States	Human cripto protein

1994
- 1994-03-08 US US08/208,008 patent/US5633147A/en not_active Expired - Lifetime
- 1994-05-12 DK DK94916791T patent/DK0759067T3/da active
- 1994-05-12 DE DE69428214T patent/DE69428214T2/de not_active Expired - Fee Related
- 1994-05-12 CA CA002184583A patent/CA2184583A1/en not_active Abandoned
- 1994-05-12 AU AU68350/94A patent/AU681406B2/en not_active Ceased
- 1994-05-12 JP JP7523424A patent/JPH09509846A/ja not_active Ceased
- 1994-05-12 AT AT94916791T patent/ATE205254T1/de not_active IP Right Cessation
- 1994-05-12 PT PT94916791T patent/PT759067E/pt unknown
- 1994-05-12 KR KR1019960704894A patent/KR970701776A/ko not_active Application Discontinuation
- 1994-05-12 EP EP00120470A patent/EP1063293A3/en not_active Withdrawn
- 1994-05-12 ES ES94916791T patent/ES2161246T3/es not_active Expired - Lifetime
- 1994-05-12 WO PCT/US1994/005476 patent/WO1995024466A1/en active IP Right Grant
- 1994-05-12 CN CN94195051A patent/CN1087344C/zh not_active Expired - Fee Related
- 1994-05-12 EP EP94916791A patent/EP0759067B1/en not_active Expired - Lifetime
- 1994-05-19 ZA ZA943465A patent/ZA943465B/xx unknown

Also Published As

Publication number	Publication date
EP1063293A2 (en)	2000-12-27
EP0759067A1 (en)	1997-02-26
PT759067E (pt)	2002-02-28
EP1063293A3 (en)	2001-07-11
DE69428214D1 (de)	2001-10-11
JPH09509846A (ja)	1997-10-07
WO1995024466A1 (en)	1995-09-14
EP0759067B1 (en)	2001-09-05
DK0759067T3 (da)	2001-10-22
EP0759067A4 (en)	1997-10-22
AU681406B2 (en)	1997-08-28
ATE205254T1 (de)	2001-09-15
US5633147A (en)	1997-05-27
DE69428214T2 (de)	2002-06-27
KR970701776A (ko)	1997-04-12
CA2184583A1 (en)	1995-09-14
ES2161246T3 (es)	2001-12-01
CN1087344C (zh)	2002-07-10
CN1143386A (zh)	1997-02-19
AU6835094A (en)	1995-09-25

Publication	Publication Date	Title
ZA943465B (en)	1995-11-20	Transforming growth factor alpha H1
ZA943464B (en)	1995-11-20	Vascular endothelial growth factor 2
EP0787802A3 (zh)	1997-08-27
HUP0103758A2 (hu)	2002-01-28	Neurotróf faktorok
NZ271756A (en)	1998-02-26	Human macrophage inflammatory proteins and coding sequences, their production and use
HK1008787A1 (en)	1999-05-21	N-terminally monopegylated polypeptides and process for their preparation.
EP0853121A3 (en)	1998-08-05	Human DNase
AU1724795A (en)	1996-07-03	Human tissue inhibitor of metalloproteinase-4
CA2050058A1 (en)	1992-02-28	Recombinant mite allergen
DE69333885D1 (en)	2006-02-23	C-c ckr-1, ein c-c chemokin rezeptor
EP0825996A4 (en)	2000-06-14	FACTOR-1 (FHF-1) HOMOLOGATED FIBROBLAST GROWTH FACTOR AND METHODS OF USE
EP0361284A3 (en)	1990-09-05	T cell growth factor
EP0209543A4 (en)	1989-07-11	FRAGMENTS OF HUMAN APOLIPOPROTEINS PEPTIDES, TYPE-SPECIFIC ANTIBODIES AND METHODS OF USE.
NZ335633A (en)	2000-10-27	Production of recombinant H. pylori polypeptides for treatment and diagnosis of H. pylori related diseases
HUT50195A (en)	1989-12-28	New peptites hindering the activity of immune system and medical compositions containing them and process for production of these peptides and compositions
EP0587571A4 (en)	1995-03-15	HUMAN GALANINE, cDNA CLONES ENCODING HUMAN GALANINE AND PROCESS FOR PRODUCING HUMAN GALANINE.
GB2171703B (en)	1989-11-15	Expression-secretion vector for gene expression and protein secretion, recombinant dna including the vector, and method of producing proteins by use of the re
NO890174L (no)	1989-07-17	Rekombinante interleukin-1alfa-polypeptider.
WO2003014293A3 (en)	2003-12-24	Novel polypeptide analogs and fusions and their methods of use
CA2089111A1 (en)	1993-08-11	Smooth muscle mitogen and isolated dna coding therefor
EP0832109A4 (en)	2000-06-14	FIBROPLAST GROWTH FACTOR APPROVED FACTOR-2 AND METHODS OF USE
EP0780472A3 (en)	1998-05-20	Stress proteins
CA2050477A1 (en)	1991-07-09	T cell growth factor
AU2459188A (en)	1989-05-04	Anticoagulative protein pp4-x, and its preparation and use
WO2001075008A3 (fr)	2002-02-07	Nouveau polypeptide, protéine hélicase-anneau-hélicase 11, et polynucleotide codant pour ce polypeptide